Clinical Trials · NCT05304169
Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
- Enrollment
- 48
- Start date
- Nov 2017
- Locations
- 6 sites, Brazil
- Primary endpoint
- Baseline testosterone levels (≤50 ng/dL)